Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | Ponatinib and its role in treating ALL

Susan O’Brien • 1 Jun 2017
ASCO 2017
Acute Lymphoblastic Leukemia Inotuzumab ozogamicin Ponatinib

Susan O’Brien, MD from the University of California, Irvine, CA discusses the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. She explains the need to carefully adjust doses of ponatinib in treating patients due to the drug’s association with vascular events, as evaluated in a Phase II trial (NCT00671658). Overall, she explains that both trials had positive results and the future for treating ALL seems to be promising.

More from Susan O’Brien

2:03
Venetoclax and obinutuzumab combination therapy for CLL
Susan O’Brien • 14 Jun 2019
2:19
CAR T-cell therapy updates in CLL
Susan O’Brien • 14 Jun 2019
2:00
CLL RESONATE-2: Five-year follow-up
Susan O’Brien • 13 Jun 2019
3:19
Zanubrutinib and acalabrutinib for CLL: potential alternatives to ibrutinib?
Susan O’Brien • 15 Jun 2019

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
1:15
Comparing the efficacy of salvage therapies in adult B-ALL: a retrospective real-world study
Alex Rampotas • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals